You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,253,076


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,253,076
Title:Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventor(s): Mahr; Andrea (Tuebingen, DE), Weinschenk; Toni (Aichwald, DE), Hoerzer; Helen (Tuebingen, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Munich, DE)
Assignee: IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)
Application Number:15/199,066
Patent Claims:1. A method for the treatment of a patient who has cancer, comprising administering to the patient a population of activated T lymphocyte that selectively recognizes cancer cell, which presents a peptide consisting of the amino acid sequence of HLTEVYPEL (SEQ ID NO: 5) wherein said cancer is selected from the group consisting of ovarian cancer, non-small cell lung cancer, small cell lung cancer, kidney cancer, brain cancer, colon or rectum cancer, stomach cancer, liver cancer, pancreatic cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma, melanoma, esophageal cancer, urinary bladder cancer, uterine cancer, gallbladder cancer, and bile duct cancer.

2. A method of claim 1, wherein said cancer is urinary bladder cancer.

3. The method of claim 1, wherein the T cells are autologous to the patient.

4. The method of claim 1, wherein the T cells are obtained from a healthy donor.

5. The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

6. The method of claim 1, wherein the activated T cells are expanded in vitro.

7. The method of claim 1, wherein the peptide is in a complex with an MHC molecule.

8. The method of claim 1, wherein the activated T cells are produced by contacting T cells with the peptide/MHC molecule complex expressed on the surface of an antigen-presenting cell for a period of time sufficient to activate the T cells.

9. The method of claim 8, wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.

10. The method of claim 9, wherein the antigen presenting cell is a dendritic cell or a macrophage.

11. The method of claim 6, wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.

12. The method of claim 1, wherein the population of activated T cells comprises CD8-positive cells.

13. The method of claim 8, wherein the contacting is in vitro.

14. The method of claim 1, wherein the population of activated T cells are administered in the form of a composition.

15. The method of claim 14, wherein the composition comprises an adjuvant.

16. The method of claim 15, wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivates, poly-(I:C) and derivates, RNA, sildenafil, particulate formulations with poly(lactid co-glycolid) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

17. The method of claim 7, wherein the MHC molecule is a class I MHC molecule.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.